PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07D 213/73, A61K 31/44, A61P 25/00 — A1

(11) International Publication Number: **WO 00/50400**

(43) International Publication Date: 31 August 2000 (31.08.00)

(21) International Application Number: PCT/IB00/00109

(22) International Filing Date: 2 February 2000 (02.02.00)

(30) Priority Data:
60/121,597 25 February 1999 (25.02.99) US

(71) Applicant *(for all designated States except US)*: PFIZER PRODUCTS INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: LOWE, John, Adams, III [US/US]; 28 Coveside Lane, Stonington, CT 06378 (US).

(74) Agents: SPIEGEL, Allen, J. et al ; Pfizer Inc , Patent Dept., 235 East 42nd Street, New York, NY 10017 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.




G00001

(54) Title: 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS

(57) Abstract

The present invention relates to 2-aminopyridine derivatives of formula (I) or pharmaceutically acceptable salts thereof, wherein A and B are each independently H, or together, A and B form a ring fused to the phenyl ring, said ring being satured or unsatured and containing from 5 to 7 ring member atoms, where said ring member atoms may optionally comprise from 1 to 2 heteroatoms selected independently from the group consisting of N, O or S, provided that no two adjacent ring members are heteroatoms; X is oxygen or a single bond; Y is (C_1–C_6)alkyl; R^1 is hydrogen, (C_1–C_6)alkyl or a (C_1–C_6 alkyl) group substituted with $-NR^2R^3$ wherein R^2 and R^3 are either selected independently from the group consisting of H, alkyl, aryl, aralkyl or tetrahydronaphthalene, wherein said aryl group or said aryl moiety of said aralkyl group is phenyl or naphthyl, said alkyl group or said alkyl moiety of said aralkyl group contains from one to six carbon atoms and is straight-chained or branched, and said aryl group, said tetrahydronaphthalene or said aryl moiety of said aralkyl group is optionally substituted with from one to three of halogen, nitro, cyano, amino, (C_1–C_4)alkoxy and (C_1–C_4)alkylamino moieties, or R^2 and R^3 form, together with the nitrogen to which they are attached, a heterocyclic ring, or a cyclic or bicyclic ring which is saturated or unsaturated. The compounds of the invention have the ability to inhibit the activity of nitric oxide synthases (NOS), and hence, are useful in the treatment of diseases, conditions and disorders of the central nervous system, among others.



(I)



162162